Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,210 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Safety in Healthy Volunteers Clear all

Conditions: Systemic Lupus Erythematosus
Interventions: DS-7011a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Long Beach, California • San Antonio, Texas

Conditions: Ovarian Cancer, Healthy Volunteers
Interventions: Tc 99m EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Epilepsy
Interventions: Placebo, BIA 2-093 3000 mg once daily, BIA 2-093 3600 mg once daily; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Major Depressive Disorder
Interventions: LY03005, Placebo, Meal, Pristiq; Drug · Other
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: S-equol, Placebo; Drug
Lead sponsor: Ausio Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Hepatic Impairment, Healthy
Interventions: ONO-2745 /CNS 7056; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 3
States / cities: Anaheim, California • Orlando, Florida • South Miami, Florida

Conditions: Typhoid Fever
Interventions: BB IND 6989; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer's Disease
Interventions: LY2811376, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy, Alzheimer Disease
Interventions: AL002, Saline Solution; Biological · Other
Lead sponsor: Alector Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 1 more

Conditions: Parkinson's Disease
Interventions: MEDI1341, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Healthy
Interventions: CTP-692, Placebo; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Insomnia
Interventions: 20 mg VEC-162, 50 mg VEC-162, 100 mg VEC-162, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 16 more

Conditions: Pharmacokinetic Analysis
Interventions: Deupirfenidone, Pirfenidone (PFD), Placebo; Drug
Lead sponsor: PureTech; Industry
Eligibility: 60 Years to 80 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Long Beach, California • Lake Mary, Florida • Berlin, New Jersey

Conditions: Healthy Subjects
Interventions: MGD010, Placebo, Hepatitis A vaccine; Drug · Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Cilofexor, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: DSM265, Placebo, Sporozoites, Infective mosquito bite; Drug · Biological
Lead sponsor: Medicines for Malaria Venture; Other
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cytomegalovirus Infection
Interventions: MBX400, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Healthy
Interventions: Oritavancin, Placebo (D5W); Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Netherton Syndrome
Interventions: BCX17725, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more

Conditions: Healthy Volunteer
Interventions: eliglustat; digoxin, digoxin; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: MRSA, SSTI
Interventions: EDP-322; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions: Vodobatinib (K0706) capsules; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 8
States / cities: Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more

Conditions: Hepatic Impairment
Interventions: seladelpar; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Healthy
Interventions: CDX-301; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

Safety, Tolerability and Pharmacokinetics Study of LY03005

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine

A Safety Study of LY2811376 Single Doses in Healthy Subjects

A Phase I Study for Safety and Tolerability of AL002.

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

Phase 1 Study of MGD010 in Healthy Subjects

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

DSM265 Prophylaxis of Plasmodium Falciparum Malaria

Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults

Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers